ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    Prurisol | psoriasis

Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02101216
Recruitment Status : Completed
First Posted : April 2, 2014
Last Update Posted : October 26, 2018
Sponsor:
Information provided by (Responsible Party):
Innovation Pharmaceuticals, Inc. ( Cellceutix Corporation )

Brief Summary:
Cellceutix Corporation has created a new chemical entity for the treatment of psoriasis, termed Prurisol™, which is an ester of abacavir. This first-in-human study of Prurisol (abacavir acetate) is being performed to evaluate the pharmacokinetics, safety and tolerance of a single oral doses of Prurisol administered to healthy volunteers and the bioequivalence to abacavir sulfate (Ziagen). This study will be followed by a 505(b)(2) Phase 2 trial in patients with moderate to severe plaque psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Prurisol Drug: Ziagen Phase 1

Detailed Description:

Prurisol™, abacavir acetate, is an ester of abacavir. Prurisol is believed to act as an immune response modifier in certain conditions, including psoriasis. Abacavir is a synthetic nucleoside analogue. Ziagen, abacavir sulfate, was developed and marketed as a treatment for HIV-1 infection for over a decade. Ziagen inhibits viral DNA synthesis. Consequently, Prurisol is under consideration as a possible new therapy for moderate to severe plaque psoriasis. The nonclinical efficacy of Prurisol has been demonstrated in the human psoriatic skin xenograft model in irradiated severe combined immune deficient mice. Histologic as well as visual observations confirmed a treatment benefit of Prurisol in this animal model. Interleukin-20 (IL-20) is a recently discovered cytokine displaying increased levels in psoriatic lesions, and levels of IL-20 have been shown to decrease with anti-psoriasis treatment and correlate with clinical improvement. IL-20 has been suggested as a specific target in psoriasis treatment. In comparison to vehicle-treated animals, the mice transplanted with human psoriatic tissue and treated with Prurisol had significant reductions in plasma IL-20 levels which were greater than those seen with methotrexate treatment. The expression of PRINS (psoriasis susceptibility-related RNA gene induced by stress) was significantly lower with twice daily Prurisol treatment compared to control.

This study is designed as an open-label, randomized, 2-period, 2-treatment, 2-sequence, single-dose intensive pharmacokinetic (PK) study conducted in healthy volunteers. In addition, a lead-in dosing period will allow the evaluation of the PK of abacavir from 3 escalating single doses of Prurisol (50mg, 100mg, 200mg). Completion of each dosing cohort will be followed by a 24-hour safety evaluation period before moving to a higher dose. Adverse Events, vital signs, physical examination, and safety laboratory tests (clinical chemistry and hematology) from each dosed cohort will be reviewed prior to any dose escalation for next cohort.

For each subject completing the first part, there will be a 5 to 21 day washout period before the next dose of study drug. Subjects will be randomly assigned to receive either a single dose of 350mg Prurisol or 300mg of Ziagen in the second dosing period. After a 5 to 21 day washout period, subjects will receive the alternate treatment in the third dosing period.

Blood samples for PK analysis will be obtained over a 24 hour period for each dose. Safety and tolerability will be assessed by ascertainment of adverse events, results of clinical laboratory testing and physical examination.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Randomized, Open-Label, Single-Dose, 2 Period Crossover Pharmacokinetic and Bioequivalence Study, With a Lead-In Dose Period, Evaluating Oral Abacavir Acetate (Prurisol™) and Oral Abacavir Sulfate (Ziagen®) in Healthy Volunteers
Study Start Date : March 2014
Actual Primary Completion Date : July 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Pharmacokinetics of low dose Prurisol
Pharmacokinetics of single dose of Prurisol™ 50 mg (1 tablets) to 6 subjects
Drug: Prurisol
Experimental Drug
Other Name: abacavir acetate

Experimental: Pharmacokinetics medium dose Prurisol
Pharmacokinetics of single dose of Prurisol™ 100 mg (2 tablets) to 6 subjects
Drug: Prurisol
Experimental Drug
Other Name: abacavir acetate

Experimental: Pharmacokinetics of high dose Prurisol
Pharmacokinetics of single dose of Prurisol™ 200 mg (4 tablets) to 6 subjects
Drug: Prurisol
Experimental Drug
Other Name: abacavir acetate

Experimental: Bioequivalence of Prurisol (350 mg)
Single dose of Prurisol™ 350 mg (7 x 50 mg tablets)
Drug: Prurisol
Experimental Drug
Other Name: abacavir acetate

Active Comparator: Bioequivalence of Ziagen (300 mg)
Single dose of Ziagen 300 mg (1 x 300mg tablet)
Drug: Ziagen
Active comparator
Other Name: abacavir sulfate




Primary Outcome Measures :
  1. Area under the plasma concentration versus time curve (AUC) of abacavir derived from Prurisol and Ziagen [ Time Frame: 24 hours after second and third dose of study drug or reference drug ]

    Part B of the study will determine the average bioequivalence of abacavir derived from Prurisol (abacavir acetate) 350mg compared with abacavir derived from the commercially available tablet formulation of Ziagen (abacavir sulfate) 300mg.

    After completion of Part A, subjects will be randomly assigned to cross-over treatment sequence Prurisol then Ziagen, or Ziagen then Prurisol. Five to 21 days later, each subject will receive the alternate study drug. Evaluable subjects in the PK population will be those who received both alternate treatments and for whom an adequate number of post-dose PK sample results are available.


  2. Peak plasma concentration (Cmax) of abacavir derived from Prurisol and Ziagen [ Time Frame: 24 hours after second and third dose of study drug or reference drug ]

    Part B of the study will determine the average bioequivalence of abacavir derived from Prurisol (abacavir acetate) 350mg compared with abacavir derived from the commercially available tablet formulation of Ziagen (abacavir sulfate) 300mg.

    After completion of Part A, subjects will be randomly assigned to cross-over treatment sequence Prurisol then Ziagen, or Ziagen then Prurisol. Five to 21 days later, each subject will receive the alternate study drug. Evaluable subjects in the PK population will be those who received both alternate treatments and for whom an adequate number of post-dose PK sample results are available.


  3. Time to Cmax (Tmax) of abacavir derived from Prurisol and Ziagen [ Time Frame: 24 hours after second and third dose of study drug or reference drug ]

    Part B of the study will determine the average bioequivalence of abacavir derived from Prurisol (abacavir acetate) 350mg compared with abacavir derived from the commercially available tablet formulation of Ziagen (abacavir sulfate) 300mg.

    After completion of Part A, subjects will be randomly assigned to cross-over treatment sequence Prurisol then Ziagen, or Ziagen then Prurisol. Five to 21 days later, each subject will receive the alternate study drug. Evaluable subjects in the PK population will be those who received both alternate treatments and for whom an adequate number of post-dose PK sample results are available.



Secondary Outcome Measures :
  1. Area under the plasma concentration versus time curve (AUC) of abacavir derived from Prurisol [ Time Frame: 0 to 24 hours after the first dose of study drug ]

    Pharmacokinetic parameters (AUC, Cmax, Tmax, t1/2) of abacavir derived from Prurisol will be determined in Part A of this study. Three cohorts, each comprising 6 subjects, will be administered escalating single doses of Prurisol.

    Part A consists of single doses of open-label Prurisol at doses of 50mg (1 tablet), 100mg (2 tablets) and 200 mg (4 tablets) administered to approximately equal numbers of male and female subjects. These treatments will be administered in 3 sequential cohorts with at least a 24 hour interval (safety period) between subjects in each of the 3 cohorts.

    Plasma concentrations of abacavir will be assayed by a validated liquid chromatography-mass spectrometry (LC/MS/MS) method and PK parameters will be calculated.


  2. Peak plasma concentration (Cmax) of abacavir derived from Prurisol [ Time Frame: 0 to 24 hours after the first dose of study drug ]

    Pharmacokinetic parameters (AUC, Cmax, Tmax, t1/2) of abacavir derived from Prurisol will be determined in Part A of this study. Three cohorts, each comprising 6 subjects, will be administered escalating single doses of Prurisol.

    Part A consists of single doses of open-label Prurisol at doses of 50mg (1 tablet), 100mg (2 tablets) and 200 mg (4 tablets) administered to approximately equal numbers of male and female subjects. These treatments will be administered in 3 sequential cohorts with at least a 24 hour interval (safety period) between subjects in each of the 3 cohorts.

    Plasma concentrations of abacavir will be assayed by a validated liquid chromatography-mass spectrometry (LC/MS/MS) method and PK parameters will be calculated.


  3. Time to Cmax (Tmax) of abacavir derived from Prurisol [ Time Frame: 0 to 24 hours after the first dose of study drug ]

    Pharmacokinetic parameters (AUC, Cmax, Tmax, t1/2) of abacavir derived from Prurisol will be determined in Part A of this study. Three cohorts, each comprising 6 subjects, will be administered escalating single doses of Prurisol.

    Part A consists of single doses of open-label Prurisol at doses of 50mg (1 tablet), 100mg (2 tablets) and 200 mg (4 tablets) administered to approximately equal numbers of male and female subjects. These treatments will be administered in 3 sequential cohorts with at least a 24 hour interval (safety period) between subjects in each of the 3 cohorts.

    Plasma concentrations of abacavir will be assayed by a validated liquid chromatography-mass spectrometry (LC/MS/MS) method and PK parameters will be calculated.


  4. Elimination half-life (t1/2) of abacavir derived from Prurisol [ Time Frame: 0 to 24 hours after the first dose of study drug ]

    Pharmacokinetic parameters (AUC, Cmax, Tmax, t1/2) of abacavir derived from Prurisol will be determined in Part A of this study. Three cohorts, each comprising 6 subjects, will be administered escalating single doses of Prurisol.

    Part A consists of single doses of open-label Prurisol at doses of 50mg (1 tablet), 100mg (2 tablets) and 200 mg (4 tablets) administered to approximately equal numbers of male and female subjects. These treatments will be administered in 3 sequential cohorts with at least a 24 hour interval (safety period) between subjects in each of the 3 cohorts.

    Plasma concentrations of abacavir will be assayed by a validated liquid chromatography-mass spectrometry (LC/MS/MS) method and PK parameters will be calculated.


  5. Number of participants with adverse events [ Time Frame: Day 1, Day 2, Day 3 ]

    To evaluate the safety and tolerability of Prurisol in healthy volunteers, completion of each dosing cohort will be followed by a 24-hour safety evaluation period before moving to a higher dose. Adverse events from each dosed cohort will be reviewed prior to any dose escalation for next cohort.

    For each subject completing their first treatment, there will be a 5 to 21 day washout period before being given the next dose of study drug. Subjects completing their first treatment will be randomly assigned to receive either Prurisol or Ziagen in the second dosing period. After a 5-21 day washout period, subjects will receive the alternate treatment (Ziagen or Prurisol) in the third dosing period.

    The sequential dosing specified will allow for observation of any possible adverse effects of Prurisol at the respective doses.


  6. Number of participants with vital sign changes [ Time Frame: Day 1, Day 2, Day 3 ]

    To evaluate the safety and tolerability of Prurisol in healthy volunteers, completion of each dosing cohort will be followed by a 24-hour safety evaluation period before moving to a higher dose. Vital signs from each dosed cohort will be reviewed prior to any dose escalation for next cohort.

    For each subject completing their first treatment, there will be a 5 to 21 day washout period before being given the next dose of study drug. Subjects completing their first treatment will be randomly assigned to receive either Prurisol or Ziagen in the second dosing period. After a 5-21 day washout period, subjects will receive the alternate treatment (Ziagen or Prurisol) in the third dosing period.

    The sequential dosing specified will allow for observation of any possible adverse effects of Prurisol at the respective doses.


  7. Number of participants with changes in standard laboratory tests [ Time Frame: Day 1, Day 2, Day 3 ]

    To evaluate the safety and tolerability of Prurisol in healthy volunteers, completion of each dosing cohort will be followed by a 24-hour safety evaluation period before moving to a higher dose. Laboratory tests (standard hematology and clinical chemistry panels) from each dosed cohort will be reviewed prior to any dose escalation for next cohort.

    For each subject completing their first treatment, there will be a 5 to 21 day washout period before being given the next dose of study drug. Subjects completing their first treatment will be randomly assigned to receive either Prurisol or Ziagen in the second dosing period. After a 5-21 day washout period, subjects will receive the alternate treatment (Ziagen or Prurisol) in the third dosing period.

    The sequential dosing specified will allow for observation of any possible adverse effects of Prurisol at the respective doses.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Individuals who meet ALL of the following criteria are eligible for participation in this study:

  • Provided written informed consent
  • Male or female adult aged 18-65 years old (inclusive). At least 20% of enrolled subjects will be aged 55-65 years, inclusive. Effort will be made to enroll equivalent numbers of males and females
  • BMI of 19-32 kg/m2
  • Identified as a non-smoker at the Consent/Screening Visit. A urine cotinine test will be performed at screening and during each clinic check-in before for each of the three Treatment Visits
  • Willing and able to comply with all aspects of the study protocol including avoiding use of certain concomitant medications and attending the required clinic visits

Exclusion Criteria:

Subjects are not eligible for participation in the study if any of the following criteria are met:

  • Females of childbearing potential not using reliable contraception, (e.g., abstinence, double barrier method, oral/implantable/transdermal contraception. Depo-provera, intrauterine device)
  • Female who is pregnant, lactating, has a positive serum pregnancy test drawn at the Consent/Screening Visit, or has a positive urine pregnancy test at check-in performed prior to any of the 3 Treatment Days
  • Presence of any uncontrolled (in the Investigator's medical opinion) systemic disease, including, but not limited to renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or psychiatric disease
  • History of any immune disorder, or disease/condition potentially affecting the immune system
  • Regular use of oral or parenteral corticosteroids (inhaled corticosteroids for stable asthma or chronic obstructive pulmonary disease are permitted)
  • ECG obtained at Consent/Screening Visit which shows medically significant abnormalities (e.g. bundle branch block, frequent premature ventricular contractions, corrected QT interval (QTc) prolongation >450 msec for males and >470 msec for females)
  • Presence of a condition that makes it unlikely that the requirements of the protocol will be completed
  • Urine screening test(s) positive for evidence of amphetamines, barbiturates, benzodiazepines, cocaine, methamphetamine, opiates, phencyclidine, marijuana
  • Positive urine cotinine test
  • Positive breath alcohol test
  • History of hypersensitivity to any formulation of abacavir
  • Previous treatment with any abacavir-containing product
  • Current participation or participation in a drug/device or biologic investigational research study within 30 days prior to the Treatment A Visit
  • An elective surgical or medical procedure is planned or scheduled to be performed during the period of the study
  • Past surgical history of any degree of gastric resection or gastric banding
  • History of a clinically diagnosed upper respiratory tract infection or any acute illness requiring antibiotic therapy within 14 days prior to the Treatment A Visit
  • Systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg or heart rate <45 bpm in a subject under the age of 40 years and heart rate <50 bpm in a subject aged ≥40 years or >100 bpm (any subject age) on repeat determinations at the Consent/Screening Visit or at check-in on the day prior to each of the 3 Treatment Days and at pre-dose if drug administered on different day than check-in
  • Clinical laboratory results at the Consent/Screening Visit that show any one or more of the following:

    • Hemoglobin <11 Gm/dL, Hematocrit<30%
    • Total white blood cell count <3000cells/mm3
    • Absolute neutrophil count <1500cells/mm3
    • Platelet count <100,000/mm3
    • alanine aminotransferase or aspartate aminotransferase >1.5 x Upper Limit of Normal (ULN)
    • Serum amylase above ULN
    • Serum creatinine >1.5 x ULN
    • Positive serum human chorionic gonadotropin
    • Positive serologic test for HBsAg, HIV, hepatitis C virus
    • Positive test for HLA-B*5701 allele by certified laboratory
    • Urinalysis showing medically significant abnormality

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02101216


Locations
United States, Florida
Phase One Solutions Inc.
Miami Gardens, Florida, United States, 33169
Sponsors and Collaborators
Cellceutix Corporation
Investigators
Study Director: Krishna Menon Cellceutix Corporation

Additional Information:
Publications:
Responsible Party: Cellceutix Corporation
ClinicalTrials.gov Identifier: NCT02101216     History of Changes
Other Study ID Numbers: CTIX-14-03
First Posted: April 2, 2014    Key Record Dates
Last Update Posted: October 26, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Innovation Pharmaceuticals, Inc. ( Cellceutix Corporation ):
bioequivalence
pharmacokinetics
psoriasis

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Abacavir
Dideoxynucleosides
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Antimetabolites